Lonza has completed the carve-out of its Lonza Specialty Ingredients, as announced in February. The business, temporarily known as LSI, will be relaunched shortly under a different name. It is now owned by Herens HoldCo, an entity controlled by private equity firms Bain Capital and Cinven, who acquired it for an enterprise value of CHF 4.2 billion.

Following a long period of speculation, Lonza has entered into a definitive agreement to sell its Lonza Specialty Ingredients (LSI) business to private equity firms Bain Capital and Cinven for CHF 4.2 billion in order to focus entirely on healthcare. The deal is expected to close in 2H, subject to customary closing conditions.

Lonza has reported 7.7% growth in sales in constant currency terms during 1H 2020 to CHF 3,074 million, with a core EBITDA margin of 29.1%. This, as in 2019, was largely driven by the Lonza Pharma Biotech & Nutrition (LBPN) segment, which had 10.8%3 sales growth and a margin of 34.1%.